Ligand-conjugated mesoporous silica nanorattles based on enzyme targeted prodrug delivery system for effective lung cancer therapy

Toxicology and Applied Pharmacology

Volumn 275, Issue 3, 2014, Pages 232-243

  Sundarraj, Shenbagamoorthy ^a   Thangam, Ramar ^a,b   Sujitha, Mohanan V ^a   Vimala, Karuppaiya ^a   Kannan, Soundarapandian ^a,c  

^a BHARATHIAR UNIVERSITY   (India)

^b King Institute of Preventive Medicine and Research   (India)

^c PERIYAR UNIVERSITY   (India)

Author keywords

CPLA2 activity; Drug delivery system (DDS); Epidermal growth factor receptor (EGFR); Lung cancer therapy; Pyrrolidine 2; Silica nanorattles

Indexed keywords

ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LIGAND; PYRROLIDINE DERIVATIVE; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LUNG ALVEOLUS CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN;

MUS;

CPLA(2)Α ACTIVITY; DRUG DELIVERY SYSTEM (DDS); EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR); LUNG CANCER THERAPY; PYRROLIDINE-2; SILICA NANORATTLES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARACHIDONIC ACID; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; ENDOCYTOSIS; GROUP IV PHOSPHOLIPASES A2; HUMANS; IMMUNOCONJUGATES; LIGANDS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PRODRUGS; PYRROLIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SILICON DIOXIDE; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896719643     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.01.012     Document Type: Article

References (55)

1. Chen Y., Chen H., Guo L., He Q., Chen F., Zhou J., Feng J., Shi J. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano 2010, 4:529-539.
2. Fontanini G., De Laurentiis M., Vignati S., Chine S., Lucchi M., Silvestri V., Mussi A., De Placido S., Tortora G., Bianco A.R., Gullick W., Angeletti C.A., Bevilacqua G., Ciardiello F. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. 1998, 4:241-249.
3. Fujino S., Enokibori T., Tezuka N., Asada Y., Inoue S., Kato H. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur. J. Cancer 1996, 32:2070-2074.
4. Gao F., Li L., Liu T., Hao N., Liu H., Tan L., Li H., Huang X., Peng B., Yan C., Yang L., Wu X., Chen D., Tang F. Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects. Nanoscale 2012, 74:3365-3372.
5. Ghomashchi F., Stewart A., Hefner Y., Ramanadham S., Turk J., Leslie C.C., Gelb M.H. A pyrrolidine-based specific inhibitor of cytosolic phospholipase A(2)alpha blocks arachidonic acid release in a variety of mammalian cells. Biochim. Biophys. Acta 2001, 1513:160-166.
6. Ghosh M., Loper R., Ghomashchi F., Tucker D.E., Bonventre J.V., Gelb M.H., Leslie C.C. Function, activity and membrane targeting of cytosolic phospholipase A2zeta in mouse lung fibroblasts. J. Biol. Chem. 2007, 282:11676-11686.
7. Grünwald V., Hidalgo M. The epidermal growth factor receptor: a new target for anticancer therapy. Curr. Probl. Cancer 2002, 26:109-164.
8. Heasley L.E., Thaler S., Nicks M., Price B., Skorecki K., Nemenoff R.A. Induction of cytosolic phospholipase A2 by oncogenic Ras in human nonsmall cell lung cancer. J. Biol. Chem. 1997, 272:14501-14504.
9. Herbert S.P., Ponnambalam S., Walker J.H. Cytosolic phospholipase A2-α mediates endothelial cell proliferation and is inactivated by association with the Golgi apparatus. Mol. Biol. Cell 2005, 16:3800-3809.
10. Herbert S.P., Odell A.F., Ponnambalam S., Walker J.H. Activation of cytosolic phospholipase A2-α as a novel mechanism regulating endothelial cell cycle progression and angiogenesis. J. Biol. Chem. 2009, 284:5784-5796.
11. Hu Y., Zheng X.T., Chen J.S., Zhou M., Li C.M., Lou X.W. Silica-based complex nanorattles as multifunctional carrier for anticancer drug. J. Mater. Chem. 2011, 21:8052-8056.
12. Korystov Y.N., Shaposhnikova V.V., Levitman M., Kudryavtsev A.A., Kublik L.N., Narimanov A.A. The effect of inhibitors of arachidonic acid metabolism on proliferation and death of tumor cells. FEBS Lett. 1998, 431:224-226.
13. Lagorce-Pages C., Paraf F., Wendum D., Martin A., Flejou J.F. Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus. Virchows Arch. 2004, 444:426-435.
14. Laye J.P., Gill J.H. Phospholipase A2 expression in tumors: a target for therapeutic intervention. Drug Discov. Today 2003, 8:710-716.
15. Lee J., Choi Y., Kim K., Hong S., Park H.Y., Lee T. Characterization and cancer cell specific binding properties of anti-EGFR antibody conjugated quantum dots. Bioconjug. Chem. 2010, 21:940-946.
16. Li L.L., Tang F.Q., Liu H.Y., Liu T.L., Hao N.J., Chen D., Teng X., He J. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 2010, 4:6874-6822.
17. Li L., Guan Y., Liu H., Hao N., Liu T., Meng X., Fu C., Li Y., Qu Q., Zhang Y., Ji S., Chen L., Chen D., Tang F. Silica nanorattle doxorubicin anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano 2011, 5:7462-7470.
18. Lison D., Thomassen L.C.J., Rabolli V., Gonzalez L., Napierska D., Seo J.W. Nominal and effective dosimetry of silica nanoparticles in cytotoxicity assays. Toxicol. Sci. 2008, 104:155-162.
19. Liu P., Li Z., Zhu M., Sun Y., Li Y., Wang H. Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J. Mater. Sci. Mater. Med. 2010, 21:551-556.
20. Liu H.Y., Chen D., Li L.L., Liu T.L., Tan L.F., Wu X.L. Multifunctional gold nanoshells on silica nanorattle: a novel potential platform for combination of photothermal therapy and chemotherapy with low systemic toxicity. Angew. Chem. Int. Ed. 2011, 50:891-895.
21. Liu T.L., Li L.L., Teng X., Huang X.L., Liu H.Y., Chen D. Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. Biomaterials 2011, 32:1657-1668.
22. Liu H., Liu T., Wu X., Li L., Tan L., Chen D., Tang F. Targeting gold nanoshells on silica nanorattles: a drug cocktail to fight breast tumors via a single irradiation with near-infrared laser light. Adv. Mater. 2012, 24:755-761.
23. Mamaeva V., Rosenholm J.M., Bate-Eya L.T., Bergman L., Peuhu E., Duchanoy A., Fortelius L.E., Landor S., Toivola D.M., Sahlgren C.L. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer. Mol. Ther. 2011, 19:1538-1546.
24. Melancon M.P., Lu W., Yang W., Zhang Z., Cheng R., Elliot Z., Li C. In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol. Cancer Ther. 2008, 7:1730-1739.
25. Moller K., Kobler J., Bein T. Colloidal suspensions of nanometer-sized mesoporous silica. Adv. Funct. Mater. 2007, 17:605-612.
26. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
27. Mossman B.T., Borm P., Castranova P.J., Costa V., Donaldson D.L., Kleeberger S.R. Mechanisms of action of inhaled fibers, particles and nanoparticles in lung and cardiovascular diseases. Part. Fibre Toxicol. 2007, 4:123-132.
28. Paciotti G.F., Kingston D.G., Tamarkin L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors. Drug Dev. Res. 2006, 67:47-54.
29. Reich R., Martin G.R. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 1996, 51:1-17.
30. Ritter C.A., Arteaga C.L. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 2003, 30:3-11.
31. Rosenholm J.M., Meinander A., Peuhu E., Niemi R., Eriksson J.E., Sahlgren C., Linden M. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 2009, 3:197-206.
32. Rosenholm J.M., Sahlgren C., Linden M. Cancer-cell targeting and cell-specific delivery by mesoporous silica nanoparticles. J. Mater. Chem. 2010, 20:2707-2713.
33. Rosenholm J.M., Sahlgren C., Linden M. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles-opportunities & challenges. Nanoscale 2010, 2:1870-1883.
34. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., Mclntosh J., Kurie J., Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993, 53:2379-2385.
35. Rusch V., Mendelsohn J., Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 1996, 7:133-141.
36. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 1997, 3:515-522.
37. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19:183-232.
38. Seno, K, Ohtani, M, Watanabe, F, Tamauchi, H., 1998. Patent WO98/33797.
39. Seno K., Okuno T., Nishi K., Murakami Y., Watanabe F., Matsuura T. Pyrrolidine inhibitors of human cytosolic phospholipase A (2). J. Med. Chem. 2000, 43:1041-1044.
40. Shappell S.B., Gupta R.A., Manning S., Whitehead R., Boeglin W.E., Schneider C., Case T., Price J., Jack G.S., Wheeler T.M., Matusik R.J., Brash A.R., Dubois R.N. 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001, 61:497-503.
41. Shimizu M., Nakamura H., Hirabayashi T., Suganami A., Tamura Y., Murayama T. Ser515 phosphorylation-independent regulation of cytosolic phospholipase A2α (cPLA2α) by calmodulin dependent protein kinase: possible interaction with catalytic domain A of cPLA2α. Cell. Signal. 2008, 20:815-824.
42. Slowing I.I., Trewyn B.G., Lin V.S.Y. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J. Am. Chem. Soc. 2006, 128:14792-14793.
43. 2α in non-small cell lung carcinoma. Asian Pac. J. Cancer Prev. 2010, 11:1367-1372.
44. 2α in nonsmall cell lung cancer cells. J. Cancer Res. Clin. Oncol. 2012, 138:827-835.
45. Sundarraj S., Thangam R., Sreevani V., Kaveri K., Gunasekaran P., Achiraman S., Kannan S. γ-Sitosterol from Acacia nilotica L. induces G2/M cell cycle arrest and apoptosis through c-Myc suppression in MCF-7 and A549 cells. J. Ethnopharmacol. 2012, 141:803-809.
46. Thangam R., Gunasekaran P., Kaveri K., Sridevi G., Sundarraj S., Paulpandi M., Kannan S. A novel disintegrin protein from Naja naja venom induces cytotoxicity and apoptosis in human cancer cell lines in vitro. Process Biochem. 2012, 47:1243-1249.
47. Tseng C.L., Wang T.W., Dong G.C., Wu S.Y.H., Young T.H., Shieh M.J. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 2007, 28:3996-4005.
48. Tseng C.L., Wu S.Y.H., Wang W.H., Peng C.L., Lin F.H., Lin C.C. Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 2008, 29:3014-3022.
49. Uboldi C., Giudetti G., Broggi F., Gilliland D., Ponti J., Rossi F. Amorphous silica nanoparticles do not induce cytotoxicity, cell transformation or genotoxicity in Balb/3T3 mouse fibroblasts. Mutat. Res. 2012, 745:11-20.
50. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer 1998, 77:663-669.
51. World Health Organization The Global Burden of Disease: 2004 Update 2008, World Health Organization, Geneva.
52. Xu J., Amiji M. Therapeutic gene delivery and transfection in human pancreatic cancer cells using epidermal growth factor receptor-targeted gelatin nanoparticles. J. Vis. Exp. 2012, 59:3612.
53. Yang L., Mao H., Wang Y.A., Cao Z., Peng X., Wang X. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small 2009, 5:235-243.
54. Yu K.O., Grabinski C.M., Schrand A.M., Murdock R.C., Wang W., Gu B. Toxicity of amorphous silica nanoparticles in mouse keratinocytes. J. Nanopart. Res. 2009, 11:15-24.
55. Zhang X., Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int. J. Med. Sci. 2008, 5:209-217.